Mylan receives final FDA approval for generic blood pressure tablets

By Angela McDaniels

Seattle, Dec. 19 - Mylan Laboratories Inc. said subsidiary Mylan Pharmaceuticals Inc. has received final approval from the Food and Drug Administration for its Abbreviated New Drug Application for bisoprolol fumarate tablets USP, 5 mg and 10 mg.

Bisoprolol fumarate tablets are the AB-rated generic version of Duramed Pharmaceuticals' Zebeta Tablets, 5 mg & 10 mg and had U.S. sales of roughly $27 million for the 12-month period ended June 30, the company said.

Mylan Laboratories is a pharmaceutical company based in Pittsburg that develops, licenses, manufactures, markets and distributes generic and proprietary products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.